08:07 AM EDT, 04/28/2025 (MT Newswires) -- XORTX Therapeutics ( XRTX ) , up 14% on last look in U.S. pre-market trading, on Monday said it has received a European patent covering methods of formulating xanthine oxidase inhibitors (XOI) to treat health consequences of chronically high uric acid, gout, renal, cardiovascular and other diseases linked to aberrant purine metabolism.

Including the newly granted patent, XORTX now has five granted patents in the U.S. and/or the European Union.

The company's shares were last seen up US$0.15, to US$1.22 in New York trading.